Preferred Label : BTK Degrader UBX-303061;
NCIt definition : An orally bioavailable chimeric degrader of Bruton's tyrosine kinase (BTK) comprised
of an E3 ubiquitin ligase ligand conjugated to a BTK-binding ligand, with potential
antineoplastic activity. Upon oral administration, BTK degrader UBX-303061 specifically
targets and binds, with its BTK-targeting moiety, to BTK and the E3 ubiquitin ligase
ligand moiety binds to E3 ubiquitin ligase. This catalyzes ubiquitination and proteasome-mediated
degradation of BTK, and prevents the activation of the B-cell antigen receptor (BCR)
signaling pathway. This prevents B-cell activation and BTK-mediated activation of
downstream survival pathways. This leads to an inhibition of the growth of malignant
B-cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic
tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role
in B-lymphocyte development, activation, signaling, proliferation and survival.;
Molecule name : UBX-303061; UBX 303061;
NCI Metathesaurus CUI : CL1770940;
Origin ID : C213051;
chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
